BC
AEGR

Broadfin Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Broadfin Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,361,291
Closed -$13M – 76
2016
Q3 		$13M Buy
4,361,291
+351,000
+9% +$608K 1.16% 25
2016
Q2 		$5.97M Hold
4,010,291
– – 0.58% 44
2016
Q1 		$14.8M Buy
4,010,291
+500,000
+14% +$3.1M 1.43% 20
2015
Q4 		$35.5M Buy
3,510,291
+1,189,925
+51% +$14.3M 2.18% 11
2015
Q3 		$31.6M Sell
2,320,366
-532,212
-19% -$9.48M 1.76% 11
2015
Q2 		$54.1M Buy
2,852,578
+350,000
+14% +$7.58M 2.91% 9
2015
Q1 		$65.5M Sell
2,502,578
-46,285
-2% -$1.18M 5.1% 4
2014
Q4 		$53.4M Buy
2,548,863
+1,542,301
+153% +$38.9M 4.64% 5
2014
Q3 		$33.6M Buy
1,006,562
+196,518
+24% +$6.1M 3.52% 9
2014
Q2 		$26M Buy
810,044
+460,044
+131% +$17.1M 2.54% 11
2014
Q1 		$16.2M Buy
+350,000
New +$20.5M 1.57% 21

Broadfin Capital's AEGR Position: Q4 2016 in Review

Broadfin Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 4,361,291 shares — an estimated $13M sold.

Broadfin Capital first reported a position in AEGR in Q1 2014 and held it in 11 quarters. The position peaked at $65.5M in Q1 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Broadfin Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Broadfin Capital sold 4,361,291 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $13M.
  • Broadfin Capital first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Broadfin Capital's Aegerion Pharmaceuticals position peaked at $65.5M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.